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Knowledge of the molecular networks controlling the proliferation and fate of hematopoietic 
stem cells (HSC) is essential to understand their function in maintaining blood cell 
production during normal hematopoiesis and upon clinical transplantation. Using highly 
purified stem and progenitor cell populations, we define the proliferation index and status 
of the cell cycle machinery at discrete stages of hematopoietic differentiation and during 
cytokine-mediated HSC mobilization. We identify distinct sets of cell cycle proteins that 
specifically associate with differentiation, self-renewal, and maintenance of quiescence in 
HSC and progenitor cells. Moreover, we describe a striking inequality of function among in 
vivo cycling and quiescent HSC by demonstrating that their long-term engraftment 
potential resides predominantly in the G
 
0
 
 fraction. These data provide a direct link between 
HSC proliferation and function and identify discrete molecular targets in regulating HSC cell 
fate decisions that could have implications for both the therapeutic use of HSC and the 
understanding of leukemic transformation.
 
Hematopoiesis is initiated by a rare population
of BM multipotent hematopoietic stem cells
(HSC) that is faced at each cell division with
the decision to self-renew, differentiate, migrate,
or die (1). During steady-state hematopoiesis, the
HSC population is relatively quiescent (2, 3),
but does give rise, upon cell cycle entry, to a
hierarchy of differentiating progenitor popula-
tions that undergo the massive proliferative
expansion required to replenish the blood system
every day (1). The blood-forming system is
also able to respond efficiently to hematological
stresses such as blood loss, infection, or exposure
to cytotoxic agents by expanding the HSC
population, mainly through increased numbers
of self-renewing divisions (4, 5). Thus, HSC
proliferation must be highly adaptive to ensure
both durable production of progenitor popu-
lations during steady-state hematopoiesis and
extensive, stress-induced, self-renewing prolif-
eration, without depletion of the stem cell
pool. Such precise control of blood cell pro-
duction requires appropriate regulation of cell
cycle progression, which therefore plays a funda-
mental role in determining HSC fate decisions.
Although the molecular events controlling
HSC proliferation are still poorly understood,
they are likely determined, at least in part, by
regulated expression and/or function of compo-
nents and regulators of the cell cycle machinery.
In mammals, the rate of cell proliferation is
largely determined during the G
 
1
 
 phase of the
cell cycle (6). During this period, G
 
1
 
 cyclins
bind to and activate specific cyclin-depen-
dent kinases (Cdks), thereby dictating the tim-
ing and substrate specificity of Cdk-mediated
phosphorylation of critical cellular targets, such
as the Rb family of proteins (Rb, p107, and
p130). Two families of Cdk inhibitors (Ckis)
regulate the activity of G
 
1
 
-type cyclin–Cdk
complexes: the Ink4 family (p16, p15, p18,
and p19), which blocks the activity of cyclin
D–Cdk4-6 complexes, and the Cip/Kip family
(p21, p27, and p57), which preferentially inhib-
its cyclin E–Cdk2 complexes and also acts as
a scaffold for the catalytically active cyclin
D–Cdk4-6 complexes. In quiescent cells, Ckis
are present in excess of cyclin–Cdk complexes,
which, together with the transcriptional re-
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, short-term reconstituting 
Flk-2
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pression of E2F target genes ensured by hypophosphorylated
Rb proteins (mostly p130) (7), maintain the cells in a non-
proliferating state. Mitogenic stimulation leads to induction
of D-type cyclins, which initiate Rb phosphorylation and
also titrate away Cip/Kip Ckis from cyclin E and cyclin
A–Cdk2 complexes, thereby relieving their inhibition and
allowing them to complete the hyperphosphorylation and
inactivation of Rb proteins (mostly Rb and p107). The con-
secutive release of E2F transcription factors then enables
transcriptional activation of genes required for S phase entry
and progression through mitosis, where proteolytic degrada-
tion of the mitotic cyclins finally resets the system for the
next G
 
1
 
 phase.
Several positive and negative regulators of the cell cycle
machinery have already been shown to be critical for various
aspects of HSC and/or progenitor proliferation, including
the Ckis p21, p27, p16, and p18 (8–11) and the D-type cy-
clins and their catalytic partners Cdk4-6 (12, 13). Studies
have also analyzed the proliferation rates and distribution of
cell cycle components in various subsets of hematopoietic
cells (14), including investigation by gene array of the global
status of the cell cycle machinery in HSC (15). However, an
Figure 1. Cell cycle status in the pool of multipotent bone marrow 
cells. (A) FACS sorting conditions used to purify LT-HSC, ST-HSCF, and 
MPPF. (B) Cell cycle analyses of purified populations by H/PY (top, contour 
plot) and PI (bottom, histogram) staining. The percentages of cells in G0 
(H2N/PY), G1 (H2N/PY), or S-G2/M (H2N-4N/PY) and in sub2N (2N), G0/
G1 (2N), S (2N and 4N), and/or G2/M (4N) are indicated. (C) Scheme 
of the BrdU incorporation experiment. 1 mg BrdU (n  20 mice/time 
point) was injected intraperitoneally at the start of the kinetic (t  0) and 
every 6 h thereafter, and BM cells were harvested after 1 h (t  1 h; one 
injection of BrdU), 12 h (t  12 h; two injections of BrdU), and 24 h (t 
24 h; four injections of BrdU). (D) Short-term kinetics of BrdU incorporation. 
At the indicated time after BrdU injection, each population was purified by 
double FACS sorting, and analyzed by flow cytometry for BrdU/PI staining 
(dot plots). The percentage of BrdU cells is indicated (*, potential back-
ground). Histograms (right) indicate the changes over time in BrdU fluo-
rescence intensity.
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integrated description of proliferation both at the cellular and
molecular levels, which would allow us to understand how
different sets of cell cycle proteins may be involved in con-
trolling the different cellular outcomes and fate decisions in
HSC and primitive progenitor cell populations, has yet to
be provided. Previous studies have also demonstrated that
among HSC, cells with 2N DNA content (in G
 
0
 
 or G
 
1
 
phases) exhibit enhanced capacity for radioprotection and for
long-term multilineage reconstitution when compared with
cells with 
 

 
2N DNA content (in S or G
 
2
 
/M phases) (16,
17), leading to the suggestion that HSC quiescence may pro-
mote engraftment function (15, 18), although this hypothesis
has yet to be formally tested.
In this paper, we have used our ability to isolate nearly
pure populations of mouse stem and progenitor cells to de-
scribe the molecular networks regulating their proliferation
during both normal hematopoietic differentiation and cyto-
kine-mediated HSC mobilization and to identify distinct mo-
lecular targets that specifically associate with these processes.
Furthermore, we functionally assess the impact of HSC pro-
liferation on hematopoietic repopulating potential and dem-
onstrate that long-term engraftment capacity of transplanted
HSC critically depends on maintenance of the quiescent
state. Together, these findings provide a direct link between
HSC proliferation and cell fate decisions that could have im-
plications for both the therapeutic use of HSC and the un-
derstanding of leukemic transformation.
 
RESULTS
Proliferation in the pool of multipotent BM cells
 
BM HSC can be divided into a long-term reconstituting
Flk-2
 

 
 HSC (LT-HSC) subset (Lin
 

 
/c-Kit
 

 
/Sca-1
 

 
/
Thy1.1
 
int
 
/Flk2
 

 
) capable of extensive self-renewal, a short-
term reconstituting Flk-2
 
int
 
 HSC (ST-HSC
 
F
 
) subset (Lin
 

 
/
c-Kit
 

 
/Sca-1
 

 
/Thy1.1
 
int
 
/Flk2
 
int
 
), which self-renews for a
limited interval and then gives rise to a nonself-renewing
Flk-2
 

 
 multipotent progenitor (MPP
 
F
 
) subset (Lin
 

 
/c-Kit
 

 
/
Sca-1
 

 
/Thy1.1
 

 
/Flk2
 

 
; Fig. 1 A) (19). To determine the
cell cycle profile of these populations in steady-state condi-
tions, each subset was first purified by double FACS sorting
and then analyzed both by HOECHST 33342/Pyronin Y
(H/PY) vital staining for DNA/RNA content and intracel-
lular propidium iodide (PI) staining of fixed cells for DNA
content (Fig. 1 B). An average of two thirds (69.2 
 

 
 2.4%;
 
n 
 

 
 3) of the LT-HSC population was found in the quiescent
G
 
0
 
 phase (H
 
2N
 
/PY
 

 
) of the cell cycle, whereas the remain-
ing one third was divided between the G
 
1
 
 phase (H
 
2N
 
/PY
 

 
;
20.2 
 

 
 2.5%) and the S-G
 
2
 
/M phase (H
 

 
2N-4N
 
/PY
 

 
; 9.7 
 

 
0.8%). Differentiating ST-HSC
 
F
 
 and MPP
 
F
 
 displayed a
progressive decrease in the frequency of quiescent G
 
0
 
 cells
(58.8 
 

 
 1.4% and 48.3 
 

 
 2.5%, respectively; 
 
n
 
 
 

 
 3), correlating
with an increase in the frequency of cycling G
 
1
 
 (25.3 
 

 
0.9% and 37 
 

 
 3.5%) and S-G
 
2
 
/M (15.3 
 

 
 1% and 14.5 
 

 
0.9%) cells, respectively. Intracellular PI staining also indi-
cated that each subset contained a substantial proportion
(12–16%) of cells with a sub-2N DNA apoptotic profile
(Fig. 1 B).
To analyze the proliferation changes that occur when
LT-HSC lose their self-renewal potential and differentiate
into ST-HSC
 
F
 
 and MPP
 
F
 
, we performed a short-term ki-
netic analysis of bromodeoxyuridine (BrdU) incorporation
(Fig. 1 C). Mice were injected intraperitoneally with BrdU
at the start of the experiment and every 6 h thereafter to en-
sure that constant levels of BrdU remained available in vivo,
and mice were killed at the indicated times after BrdU injec-
tion. Each subset was first purified by double FACS sorting
and then analyzed for BrdU incorporation by flow cytome-
try (Fig. 1 D). As expected, LT-HSC showed the slowest ki-
netics of BrdU incorporation with only 
 

 
5% BrdU
 

 
 cells
after 1 h and approximately one fourth (
 

 
24%) of the popu-
lation BrdU
 

 
 after 24 h. Although this percentage is consid-
erably higher than the 
 

 
8-10%/day described in a previous
report (3), we believe that it provides a better approxima-
tion of the number of cycling LT-HSC per day because the
data were obtained using a more efficient BrdU delivery sys-
tem (repeated intraperitoneal injection vs. drinking water), a
more sensitive BrdU detection system (FACS vs. immuno-
fluorescence), and a more refined combination of cell surface
markers to isolate the LT-HSC population (3, 19). Differen-
tiating ST-HSC
 
F
 
 and MPP
 
F
 
 displayed even faster kinetics of
BrdU incorporation, with 18–19% BrdU
 

 
 cells after 1 h and
more than half of each population having incorporated
BrdU after 24 h. These results indicate that although quies-
cence is the numerically dominant state of the LT-HSC, a
substantial fraction of this rare population of cells is actively
cycling and differentiating to give rise to the faster proliferat-
ing ST-HSC
 
F
 
 and MPP
 
F
 
.
 
HSC long-term engraftment potential and cell cycle status
 
We and others have previously demonstrated that cycling or
recently divided HSC have substantially reduced engraft-
ment capacity upon transplantation into lethally irradiated
hosts (16, 17). To study further the impact of cell cycle status
on HSC function in hematopoietic reconstitution, double
FACS–sorted LT-HSC and Lin
 

 
/c-Kit
 

 
/Sca-1
 

 
/Thy1.1
 
int
 
(KTLS HSC) (20) were stained with H/PY, resorted into
G
 
0
 
, G
 
1
 
 or S-G
 
2
 
/M subpopulations, and subsequently tested
for their engraftment capacity in limited dilution competi-
tive reconstitution assays (Table I). At doses of 10–50 HSC
per recipient, sustained multilineage reconstitution was ob-
served only in animals transplanted with triple-sorted G
 
0
 
 LT-
HSC or KTLS HSC (11/24 recipients of 10 G
 
0
 
 HSC and 8/
9 recipients of 50 G
 
0
 
 HSC). Furthermore, transplanted G
 
0
 
HSC generally showed increasing contributions to hemato-
poiesis over time, as indicated by increasing peripheral blood
chimerism, whereas animals transplanted with 10 or 50 LT-
HSC or KTLS HSC in either G
 
1
 
 or S-G
 
2
 
/M phases showed
little or no contribution to mature peripheral blood lineages,
and none exhibited multilineage reconstitution for 12 wk
after transplant. However, G0, G1 and S-G2/M phase LT-
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HSC subpopulations readily proliferated and differentiated in
liquid culture (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20050967/DC1), suggesting that the
engraftment defect of cycling HSC does not result from an
increased susceptibility to apoptosis or from an intrinsically
impaired capacity to proliferate and/or to differentiate. These
results indicate that the ability of HSC to functionally engraft
irradiated recipients dramatically decreases as soon as they
exit quiescence and enter G1.
Proliferation status in differentiating progenitor populations
Seeded by differentiating HSC, hematopoiesis progresses
with the production of both myeloid and lymphoid lineages
through the generation of common myeloid progenitors
(CMP; Lin/IL-7R/c-Kit/Sca-1/CD34/FcRlow) (21)
and common lymphoid progenitors (CLP; Lin/IL-7R/
Thy1.1/c-Kitint/Sca-1int) (22). Oligolineage-committed
CLP ultimately produce mature lymphocytes, including
splenic B cells (B220/CD19), whereas CMP differentiate
into megakaryocytic/erythroid progenitors (MEP; Lin/IL-
7R/c-Kit/Sca-1/CD34/FcRlow) and myelomonocytic
progenitors (GMP; Lin/IL-7R/c-Kit/Sca-1/CD34/
FcRhigh) (23), which finally produce mature myeloid cells,
including granulocytes (Gr; Gr-1/Mac-1; Fig. 2, A and B).
To analyze the changes in proliferation occurring during
lineage commitment and maturation, we performed similar
H/PY double staining analysis (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20050967/DC1) and
short-term kinetic analysis of BrdU incorporation, with intra-
peritoneal BrdU injection every 6 h (Fig. 2, C and D). Within
the myeloid lineage, CMP and MEP displayed similar profiles
of DNA content by PI staining, with 20% of the population
in S, G2, or M phase, whereas H/PY staining indicated a two-
fold higher frequency of cells in G1 phase within the CMP
compartment. Consistently, CMP showed faster kinetics of
BrdU incorporation than MEP, with 92 versus 77% of these
populations BrdU after 24 h. GMP displayed an even higher
proliferation index, with almost no quiescent G0 subpopula-
tion, approximately one third of the population in S, G2, or M
phase, and every cell BrdU after 24 h. Interestingly, approxi-
mately one third of the noncycling Gr population became
BrdU by 24 h, suggesting that it requires 18–24 h for a
Table I. HSC engraftment capacity as a function of cell cycle status
3–4 wk 9–12 wk 18 wk
Phase Cell #
Frequency 
reconstitution
(#/total)
Average chimerism
(range)
engraftment type
(#/reconstituted)
Frequency
reconstitution
(#/total)
Average chimerism
(range)
engraftment type
(#/reconstituted)
Frequency 
reconstitution
(#/total)
Average chimerism
(range)
engraftment type
(#/reconstituted)
LT-HSC
G0 10 57% (8/14) 1.1% (0.1–3.9%) 
M  L (8/8)
57% (8/14) 4.7% (0.3–15.2%)
M  L (8/8)
54% (7/13) 7.5% (0.6–23.7%)
M  L (7/7)
50 100% (5/5) 1.5% (0.1–5.8%)
M  L (5/5)
100% (5/5) 5.7% (0.5–14.3%)
M  L (5/5)
100% (5/5) 11.8% (0.3–35.3%)
M  L (4/5), L only (1/5)
G1 10 8% (1/12) 0.2%
M only (1/1)
0% (0/11) n/a 0% (0/11) n/a
50 50% (3/6) 4.2% (0.1–12.5%)
M only (3/3)
0% (0/5) n/a 0% (0/5) n/a
S-G2/M 10 0% (0/9) n/a 0% (0/9) n/a 0% (0/9) n/a
50 50% (3/6) 0.4% (0.2–0.7%)
M  L (3/3)
33% (2/6) 0.35% (0.3–0.4%)
M  L (1/2), L only (1/2)
33% (2/6) 0.15% (0.1–0.2%)
L only (2/2)
KTLS HSC
G0 10 50% (6/12) 0.7% (0.1–1.2%)
M  L (5/6), M only (1/6)
42% (5/12) 3% (0.2–10.6%)
M  L (5/5)
42% (5/12) 3.2% (0.3–8.3%)
M  L (4/5), L only (1/5)
50 100% (4/4) 0.7% (0.1–1.2%)
M  L (4/4)
100% (4/4) 2.9% (0.4–8.2%)
M  L (4/4)
100% (4/4) 3.0% (0.2–6.2%)
M  L (4/4)
G1 10 0% (0/10) n/a 0% (0/10) n/a 0% (0/10) n/a
50 25% (1/4) 0.3%
M (1/1)
0% (0/4) n/a 0% (0/4) n/a
S-G2/M 10 0% (0/10) n/a 0% (0/10) n/a 0% (0/10) n/a
50 20% (1/5) 0.6%
M  L (1/1)
20% (1/5) 0.3%
L only (1/1)
0% (0/5) n/a
LT-HSC and KTLS HSC were first double sorted from C57BL/6-Ly5.1 donor mice, stained with H/PY, resorted for cell cycle G0 (H2N/PY), G1 (H2N/PY), and S-G2/M (H2N-4N/PY) 
subpopulations and tested for their engraftment capacities by competitive reconstitution assays. 10 or 50 cells were transplanted into lethally irradiated congenic C57BL/6-
Ly5.2 recipient mice, together with 3  105 Ly5.2 helper BM cells. Recipient mice were considered to be reconstituted by Ly5.1 donor cells if the frequencies of Ly5.1 donor-
derived myeloid (M, Gr-1, or Mac-1) or lymphoid (L, B220, or CD3) cells detected in the peripheral blood at the indicated times after transplantation were greater than 
background levels (0.1% as determined by parallel analysis of untransplanted control C57BL/6-Ly5.2 mice). ML indicates multilineage reconstitution. n/a, not applicable.
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proliferative granulocyte progenitor (perhaps a GMP) to gen-
erate growth-arrested mature granulocytes (Fig. 2 C). Within
the lymphoid lineage, CLP displayed a low proliferation in-
dex, with only 35% of cells BrdU after 24 h (Fig. 2 D). Rest-
ing mature B lymphocytes did not show any BrdU incor-
poration within the time frame of the experiment, thereby
confirming that de novo production of mature B lymphocytes
from cycling lymphoid progenitors requires 24 h (23).
Collectively, these results indicate that the process of he-
matopoietic differentiation is accompanied by a progressive
reduction in the percentage of G0 cells (LT-HSC, 67%; ST-
HSC, 59%; MPP, 50%; CMP, 49%; and GMP, 4%) and a
correlative increase in the intrinsic proliferation rate of each
progenitor population, indicating that cell cycle distribution is
of critical importance for compartment dynamics and produc-
tion of the various lineages of mature blood cells. Moreover,
these results can be used to correlate the intrinsic proliferation
rates of multipotent and oligopotent precursor cells with their
population size in vivo (Fig. 3, A and B). Hence, the rare pop-
ulation of LT-HSC slowly and asynchronously differentiates
into ST-HSCF and then MPPF, both of which proliferate at
approximately three times the LT-HSC rate despite the fact
that MPPF accumulate in vivo at about twice the frequency of
ST-HSCF. Differentiation of oligolineage-committed progen-
itors is also associated with a marked proliferative expansion
whose magnitude, at least for the myelomonocytic lineage, di-
rectly correlates with the size of the corresponding popula-
tions. GMP exhibit twice the proliferation capacity of CMP
and accumulate at approximately five times their frequency. In
contrast, neither MEP nor CLP show a direct correlation be-
tween their proliferation rates and population size in vivo be-
cause both exhibit a relatively large pool size given their re-
stricted proliferation capacities. One explanation for these
expanded pool sizes could be that these cell populations have a
survival advantage, as suggested by the increased expression of
at least one key mediator of cell survival, Bcl2 (24), in MPPF
and CLP compared with LT-HSC (unpublished data).
Molecular regulation of the cell cycle machinery in stem 
and progenitor cells
To gain insights into the molecular control of proliferation
during steady-state hematopoiesis, we analyzed the expres-
Figure 2. Cell cycle status in progenitor and mature cell populations. 
(A and B) FACS sorting conditions used to purify myeloid progenitors (CMP, 
GMP, and MEP), mature Gr, lymphoid progenitors (CLP), and mature 
splenic B cells (B). (C and D) Short-term kinetics of BrdU incorporation 
(n  5 mice/time point). At the indicated time after BrdU injection, each 
population was first purified by double FACS sorting and then analyzed by 
flow cytometry for BrdU/PI staining (dot plots). The percentages of BrdU 
cells are indicated. Histograms on the left represent intracellular PI stain-
ing (with the percentage of cells in G0/G1, S, and/or G2/M indicated), and 
histograms on the right represent the changes over time in BrdU fluores-
cence intensity.
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sion levels of a select number of components and regulators
of the cell cycle machinery using quantitative real-time
RT-PCR (qRT-PCR; Fig. 3 C and Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20050967/DC1).
Within the pool of multipotent BM cells, LT-HSC ex-
pressed the highest levels of most of the Ckis and the lowest
levels of most of the cyclins. Strikingly, differentiation of LT-
HSC into ST-HSCF and then MPPF specifically correlated
with increased expression of cyclin D1, whereas the expres-
sion of the other D cyclins did not change. Differentiation
toward MPPF was also accompanied by decreased expression
of at least four Ckis (p16, p18, p27, and p57), which together
Figure 3. Proliferation index and status of the cell cycle machinery 
during hematopoietic differentiation. (A) Semilogarithmic plot giving 
the proportion of BrdU-negative stem and progenitor cells. (B) Schematic 
and color coded representation correlating the proliferation index (right) 
of each stem and progenitor compartment with their frequency in vivo 
(left). The different lineages of mature cells produced by each progenitor 
population are also indicated. B, B lymphocytes; T, T lymphocytes; NK: natural 
killer cells; E: erythrocytes; Mk: megakaryocytes; M	: macrophages. 
(C) Analysis by qRT-PCR of the expression levels of various components 
and regulators of the cell cycle machinery during hematopoietic differen-
tiation. Each value has been standardized for 
-actin expression levels. For 
each gene, the relative expression levels in stem, progenitor (prog), and 
mature cell (mature) populations are expressed as fold induction com-
pared with the levels (set to 1) detected in LT-HSC (except for cyclin B1, 
in which ST-HSCF was used instead). Results (means  SD) are obtained 
from three independently sorted sets of populations. *, P  0.001; , P  0.01; 
o, P  0.05. nd, not detectable.
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correlated with a partial relief of Rb-mediated transcriptional
repression (as evidenced by induction of cyclin A2 but not E
cyclins) and with a specific increase in the expression levels
of two mitotic cyclins, cyclin G2 and cyclin B1.
In the pool of myeloid progenitors, differentiation to-
ward GMP was specifically associated with induction of cy-
clin D2, which presumably overcame the inhibitory thresh-
old imposed by relatively high levels of Ckis (mostly p16 and
p27), as evidenced by the complete relief of Rb-mediated
transcriptional repression (both E cyclins and cyclin A2 in-
duction) and the induction of numerous mitotic cyclins in
this compartment (cyclins G1, B1, B2, and F). In contrast,
CMP and MEP did not show major induction of any D cy-
clins, expressed high levels of Ckis (mainly p18), and had
strong Rb-mediated repression of E2F target genes (almost
no E cyclins or cyclin A2 induction), but still displayed accu-
mulation of a limited number of mitotic cyclins (mostly cy-
clin G1) that likely contribute to their intrinsic proliferation
index. Previous reports have shown that myeloid progeni-
tors express higher levels of p27 and lower levels of p21 than
LT-HSC (8, 9). Strikingly, our analysis indicated that among
all myeloid progenitors, only GMP displayed this inverted
ratio of p21 and p27 (Fig. 3 C and Fig. S3).
Interestingly, lymphoid differentiation also correlated
with increased expression of one specific D cyclin, cyclin
D3, which is functionally important for lymphocyte devel-
opment (25) and was presumably able to overcome the Ckis’
inhibitory threshold and relieve Rb-mediated transcriptional
repression (cyclins E2 and A2 induction). However, CLP
did not show substantial induction of any mitotic cyclins,
suggesting that other as yet unidentified regulators may limit
their proliferation during the S or G2/M phases of the cell
Figure 4. Cell cycle status in mobilized HSC. (A) Schematic of the 
Cy/G treatment used to mobilize HSC. Mice were injected intraperitoneally 
with a single dose of Cy (4 mg/mouse) and injected subcutaneously with 
recombinant human G (5 g/mouse) for two successive days (D2 Cy/G 
treatment) or 4 successive days (D4 Cy/G treatment). For the BrdU experi-
ments, mice were injected intraperitoneally with BrdU (n  15 normal 
mice, 3 D2 mice, or 7 D4 mice, respectively, per time point) 1 h (t  1 h) or 
12 h (t  12 h, with repeated injection at 6 h) before killing them at the 
end of the D2 or D4 Cy/G treatment. Histograms illustrate the increased 
numbers of KTLS HSC found in BM, spleen (spl), blood (bld), or mpb at 
D2 and D4 Cy/G treatment compared with untreated mice (reference 4). 
(B) Intracellular PI staining analysis of DNA content. The percentages of 
cells in G0/G1, S, and/or G2/M are indicated. (C) Kinetics of BrdU incorporation. 
At the indicated times after BrdU injection, each population of HSC was 
first purified by double FACS sorting and then analyzed by flow cytometry 
for BrdU/PI staining (dot plots). The percentages of BrdU cells are indi-
cated. Histograms at the bottom indicate the changes over time in BrdU 
fluorescence intensity.
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cycle. As expected, mature hematopoietic cell populations
generally displayed low levels of cyclins and of the prolifera-
tion marker Ki67, as well as rather high levels of Ckis, con-
firming the results of the BrdU incorporation studies (Fig.
2). Together, these results provide a detailed description of
the cell cycle machinery controlling HSC and progenitors
proliferation during steady-state hematopoiesis.
Proliferation changes during HSC mobilization
Treatment with a combination of cyclophosphamide (Cy)
plus granulocyte-CSF (G) is commonly used in human clin-
ical transplantation to increase the numbers of HSC available
in the peripheral blood. In mice, as in humans, such treat-
ment drives HSC self-renewing proliferation and induces
HSC migration from the BM into the bloodstream (Fig. 4
A) (4, 5, 26). After administration of Cy plus two daily doses
of G (D2 Cy/G treatment), the BM HSC population dra-
matically expands, reaching 10–12 times the size of the
HSC compartment in untreated animals. After two addi-
tional daily doses of G (D4 Cy/G treatment), BM HSC fre-
quency declines, and HSC begin to appear in increased
numbers in mobilized peripheral blood (mpb; 10–fold in-
crease) and in spleen (100-fold increase). Previous experi-
ments have indicated that all HSC divide in response to Cy/
G treatment (4) and that mpb HSC derive from recently di-
vided BM HSC that transit through the bloodstream as they
move from the BM to the spleen (5).
To study further the mechanisms by which cell cycle pro-
gression is regulated in mobilized HSC, we analyzed KTLS
HSC for cell cycle profile (Fig. 4 B) and short-term kinetic
analysis of BrdU incorporation (Fig. 4 C) at D2 and D4 Cy/G
treatment. In comparison to untreated BM HSC, D2 BM
HSC exhibited a substantial increase in the frequency of cells
in S-G2/M phase (35.4  5.1% vs. 9.1  0.5%; n  4) and
very rapid kinetics of BrdU incorporation, with 85% of the
cells having incorporated BrdU after only 12 h, suggesting a
rapid recruitment of self-renewing HSC into cycle. Interest-
ingly, D4 BM HSC displayed an almost normal cell cycle pro-
file, with only 10.9  1.5% of cells in S-G2/M phase and lev-
els of BrdU incorporation very similar to those of untreated
BM HSC. In contrast, D4 spleen HSC showed increased pro-
liferation, with 20.5  2.3% cells in S-G2/M phase, and in-
creased levels of BrdU incorporation, with 40% BrdU cells
after 12 h. At D4, mpb HSC displayed DNA content very
similar to untreated BM HSC (8.5  1.2% cells in S-G2/M
phase), although they are found exclusively in the G0/G1 frac-
tion after another day of G administration (5). However, D4
mpb HSC displayed intermediate levels of BrdU incorpora-
tion between those of D4 BM and spleen HSC, suggesting
that HSC found in the bloodstream may derive from both re-
cently divided BM and spleen HSC. To determine whether a
subset of noncycling HSC could also be released into the
bloodstream during HSC mobilization, we analyzed BrdU in-
corporation into mpb HSC in D4 Cy/G-treated mice ex-
posed to BrdU during the final 36 h of the mobilization pro-
tocol (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20050967/DC1). Remarkably, every D4 mpb HSC
was BrdU positive after only 36 h of labeling, clearly demon-
strating that mobilized HSC are specifically released into the
bloodstream only after having recently divided.
To investigate the impact of mobilization on HSC func-
tion in hematopoietic reconstitution, we also tested double
FACS–sorted LT-HSC isolated from BM of untreated and
D2 Cy/G-treated mice for their engraftment capacity in
limited dilution competitive reconstitution assays (Table II).
Sustained multilineage reconstitution was observed in every
animal transplanted with 50 untreated BM LT-HSC. In
contrast, less than half of the animals transplanted with 50
D2 BM LT-HSC displayed enduring, multilineage hemato-
poietic engraftment. Moreover, those mice receiving D2
Table II. Engraftment capacity of mobilized BM LT-HSC
4 wk 8 wk 12–18 wk
Cell #
Frequency
reconstitution
(#/total)
Average chimerism
(range)
engraftment type
(#/reconstituted)
Frequency
reconstitution
(#/total)
Average chimerism
(range)
engraftment type
(#/reconstituted)
Frequency
reconstitution
(#/total)
Average chimerism
(range)
engraftment type
(#/reconstituted)
Untreated
BM LT-HSC
50 100% (8/8) 11.07% (2.3–22.7%)
M  L (8/8)
100% (7/7) 29.2% (6.7–56.9%)
M  L (7/7)
100% (7/7) 30.2% (6.2–56.2%)
M  L (7/7)
D2 Cy/G mobilized
BM LT-HSC
50 46% (7/15) 2.9% (0.2–12.5%)
M  L (7/7)
40% (6/15) 6.1% (0.4–26.8%)
M  L (4/6), L only (2/6)
40% (6/15) 4.6% (0.1–18.1%)
M  L (4/6), L only (2/6)
LT-HSC (Lin/c-Kit/Sca-1/Thy1.1int/Flk-2) were double FACS–sorted from BM of untreated C57BL/6-Ly5.1 donor mice or from mice subjected to the D2 Cy/G mobilization 
treatment and tested for their engraftment capacities by limited dilution competitive reconstitution assays. 50 cells were transplanted into lethally irradiated congenic C57BL/
6-Ly5.2 recipient mice together with 3  105 Ly5.2 helper BM cells. Recipient mice were considered to be reconstituted by Ly5.1 donor cells if the frequencies of Ly5.1 do-
nor-derived myeloid (M, Gr-1, or Mac-1) or lymphoid (L, B220, or CD3) cells detected in the peripheral blood at the indicated times after transplantation were greater than 
background levels (0.1% as determined by parallel analysis of untransplanted control C57BL/6-Ly5.2 mice). M  L indicates multilineage reconstitution.
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BM LT-HSC that did show donor cell engraftment exhib-
ited substantially lower (approximately sixfold) contributions
to overall blood cell chimerism as compared with those re-
ceiving untreated BM LT-HSC. These findings clearly dem-
onstrate that the 10-fold expanded population of D2 BM
HSC has considerably reduced engraftment capacity, in ac-
cordance with its increased proliferation rate.
Collectively, these results indicate that the self-renewing
proliferative response of BM HSC induced by Cy/G treatment
is only transient and that when HSC migrate to the periphery,
starting at D3 and continuing at D4, the HSC that remain in
the BM revert to normal proliferation rates (Fig. 5, A and B). In
contrast, HSC migrating to the spleen remain actively cycling
even though they may be more likely to differentiate to repop-
ulate the injured hematopoietic system than to self-renew, as
suggested by the reduction in spleen HSC frequency typically
observed after cessation of the Cy/G treatment (4). These re-
sults further clarify the ongoing debate about the origin of mo-
bilized HSC by demonstrating that HSC are rapidly released
into the bloodstream only after progressing through M phase.
Molecular regulation of the cell cycle machinery 
during HSC mobilization
Next, we investigated by qRT-PCR the mobilization-
induced changes in expression levels of key components and
regulators of the cell cycle machinery (Fig. 5 C). Self-renew-
ing proliferation in D2 BM specifically correlated with a
modest induction of cyclin D3 expression, whereas cyclin
D1 stayed unchanged and cyclin D2 levels actually de-
creased. D2 BM HSC also displayed reduced levels of all
Ckis except for p21, which was increased possibly because of
its requirement as a scaffold protein for the active cyclin
D–Cdk4-6 complexes. Together, these molecular events con-
tributed to the relief of Rb-mediated transcriptional repres-
sion (cyclins E1 and A2 induction) and to the induction of all
the mitotic cyclins tested except for cyclin G2. The impor-
tance of these changes is further attested by their later rever-
sion in D4 BM HSC, which were indistinguishable from
untreated BM HSC in terms of proliferation kinetics and
population size. Hence, D4 BM HSC showed repression of
all D cyclins, reinduction of all Ckis, and restoration of Rb-
mediated transcriptional repression, which together provide a
strong proliferation brake leading to an almost complete ab-
sence of mitotic cyclin expression. In contrast, mobilized D4
spleen HSC exhibited activated cell cycle machinery, though
they did not display induction of any D cyclins. This result
suggests that D4 spleen HSC are either becoming refractory
to mitogenic stimulation or that alternative pathways to cy-
clin D–Cdk4-6 might sense such mitogens (6). In fact, mobi-
lized D4 spleen HSC showed an easing of Rb-mediated
transcriptional repression (cyclin A2 induction), reduced ex-
pression of most of the Ckis (except for p21 and p27), and a
striking and unique induction of cyclin B1 rather than the
broad induction of all mitotic cyclins seen in self-renewing
D2 BM HSC. As expected, proliferating D2 BM HSC and
D4 spleen HSC also harbored increased expression levels of
Ki67 and of cdc-20/APC, which mediates proteolytic degra-
dation of A and B cyclins in late G2 phase. Altogether, these
results provide a comprehensive description of the molecular
networks controlling HSC proliferation during the various
phases of cytokine-mediated mobilization.
Molecular regulation of quiescence in HSC
To gain insights into how exit from quiescence and cell cy-
cle entry is regulated in LT-HSC, we also used qRT-PCR
to investigate potential changes in the expression levels of
genes known to play a role in establishing and/or maintain-
ing quiescence or in regulating the G0-to-G1 transition (27)
that occurs when LT-HSC differentiate toward MPPF or
when KTLS HSC expand in response to Cy/G treatment
(Fig. 6). Differentiation of LT-HSC into ST-HSCF was as-
sociated with a striking increase in the expression level of the
G0/G1 transition kinase cyclin C, although cyclin C was
again down-regulated at the MPPF stage. As expected, LT-
HSC predominantly expressed p130, which is mainly found
in quiescent G0 cells (7), over p107 and Rb (Fig. S3). Rb ex-
Figure 5. Proliferation index and status of cell cycle machinery 
during HSC mobilization. (A) Semilogarithmic plot giving the proportion 
of BrdU-negative HSC in untreated mice and mice that received D2 and D4 
Cy/G treatment. (B) Schematic and color-coded representation correlating 
the proliferation index of each HSC population following D2 and D4 Cy/G 
treatment with their pool size in vivo. (C) Analysis by qRT-PCR of the 
expression levels of various components and regulators of the cell cycle 
machinery following D2 and D4 Cy/G treatment. Results represent means  
SD of duplicate measurement performed on three independently sorted sets 
of HSC populations. Each value has been standardized for 
-actin expression 
levels and is expressed as fold induction compared with the levels (set to 1) 
detected in untreated BM HSC. *, P  0.001; , P  0.01; o, P  0.05.
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pression did not change during LT-HSC differentiation into
ST-HSCF and MPPF, whereas p107 levels increased from
the ST-HSCF stage and stayed elevated in MPPF, and p130
levels decreased at the MPPF stage. In contrast, the expres-
sion levels of E2F4, the partner of p130 for transcriptional
repression of E2F target genes in G0 cells and of Rb and
p107 in proliferative cells, did not change, nor did expres-
sion of E2F6, another E2F family member associated with
quiescence. The proliferative response associated with mobi-
lization did not induce changes in the expression levels of
most G0 and G0/G1 transition genes other than p130, which
was down-regulated in both proliferative D2 BM HSC and
D4 spleen HSC and conversely reexpressed to levels found
in untreated, resting BM HSC in D4 BM HSC (Fig. 6).
Collectively, these results suggest a switch from p130–E2F4
complexes to p107- and Rb-associated complexes as cells are
recruited into cycle. Most importantly, they indicate that
quiescence in LT-HSC is actively established and/or main-
tained by specific molecular mechanisms that support HSC
function in hematopoietic reconstitution.
DISCUSSION
In this paper, we demonstrate that the rare population of
adult BM LT-HSC exists in two distinct states that are both
equally important for their in vivo functions as stem cells: a
numerically dominant quiescent state, which is critical for
LT-HSC function in hematopoietic reconstitution, and a
proliferative state, which represents almost one fourth of this
population and is essential for LT-HSC functions in differ-
entiation and self-renewal. We show that when LT-HSC
exit quiescence and enter G1 as a prelude to cell division, at
least two critical events occur: first, during the G1 and subse-
quent S-G2/M phases, they temporarily lose efficient in vivo
engraftment activity while retaining in vitro differentiation
potential, and second, they select the particular cell cycle
proteins that are associated with specific developmental out-
comes (self-renewal vs. differentiation) and developmental
fates (myeloid vs. lymphoid). A growing body of published
literature already exists demonstrating the functional in-
volvement of many of these cell cycle proteins in maintain-
ing normal numbers of hematopoietic cells (9–15). In this
paper, we provide a global description of the precise stages of
hematopoietic differentiation in which such regulators likely
play a role and a comprehensive description of their relative
expression levels that can directly be used to further under-
stand these published studies and to design future experi-
ments targeting the relevant cell populations.
Our results demonstrate that LT-HSC function in he-
matopoietic reconstitution after transplantation critically de-
pends on maintenance of the quiescent state. Hence, actively
cycling G1 and S-G2/M phase LT-HSC display dramatically
impaired long-term engraftment and multilineage reconsti-
tution capabilities compared with G0 LT-HSC. Because pu-
rified G1 and S-G2/M LT-HSC readily proliferate and dif-
ferentiate in vitro, their functional deficiencies in vivo may
result in part from impaired or altered homing after intrave-
nous transplant. Such an explanation has some support from
observations in human CD34 BM progenitor cells, which
in G0/G1 phase show increased adhesiveness to stromal cells
(28) and appear to migrate to the BM of conditioned recipi-
ents with increased frequency over S-G2/M cells (17). The
recent microarray analysis of quiescent and proliferative
mouse HSC (15) also suggests the importance of migratory
molecules for establishing HSC quiescence and supports the
hypothesis that at least a component of the enhanced en-
graftment capacity of G0 LT-HSC may relate to a superior
BM homing efficiency. The demonstration that HSC cell
cycle status directly and dramatically affects HSC engraft-
ment function has important implications for human therapy
Figure 6. Molecular control of quiescence. Analysis by qRT-PCR of the 
expression levels of various regulators of G0 or G0/G1 phase transition in 
homeostatic proliferation during LT-HSC differentiation toward ST-HSCF 
and MPPF and stress-induced HSC self-renewing proliferation following D2 
and D4 Cy/G treatment. The results represent the means  SD of duplicate 
measurements performed on three independently sorted sets of popula-
tions. Each value has been standardized for 
-actin expression levels and is 
expressed as fold induction compared with the levels (set to 1) detected in 
LT-HSC or untreated BM HSC. *, P  0.001; , P  0.01; o, P  0.05.
JEM VOL. 202, December 5, 2005 1609
ARTICLE
because cycling HSC derived from mpb or from ex vivo–
expanded HSC cultures are commonly used, or proposed for
use, in clinical transplantation. It suggests that strategies de-
signed to reestablish quiescence in HSC before transplanta-
tion should dramatically improve their efficiency. A detailed
investigation of cycling and resting HSC is now essential to
address completely the functional relationship between their
proliferation, homing, and engraftment capacity. In this con-
text, the analysis of HSC cell cycle progression and regula-
tion during homeostatic HSC maintenance, induced HSC
expansion, and HSC differentiation (Fig. 7) presented here
provides a molecular foothold from which such functional
relationships can be further examined.
Because cycling LT-HSC display impaired function in he-
matopoietic reconstitution, one may wonder whether non-G0
LT-HSC should be called LT-HSC at all, as the name stands
for long-term reconstituting cells. Historically, LT-HSC have
been identified and isolated based on their ability to reconsti-
tute the blood system of an irradiated host. With the evolution
of the stem cell field, LT-HSC are now more precisely de-
fined by their unique ability to balance self-renewal and differ-
entiation division without depletion of the stem cell pool.
This definition implies that LT-HSC must contain a prolifera-
tive component to fulfill both self-renewal and differentiation
divisions. In fact, it has been shown that the only precursors
for LT-HSC in mouse BM are the LT-HSC themselves (29),
and as all LT-HSC enter cell cycle at least once every 15–30 d
(3), the products of LT-HSC division must include G0 phase
LT-HSC. It is also important to note that although our analy-
sis does demonstrate a substantially more robust capacity for
hematopoietic reconstitution in the G0 fraction of LT-HSC,
these data do not exclude the existence of less potent engraft-
ment potential within other cell cycle stages. In previous ex-
periments (16, 30), though reduced compared with G0/G1
cells, long-term multilineage engraftment function could be
detected within the S-G2/M population when large numbers
of these cells were transplanted. Thus, LT-HSC at all cell cy-
cle stages do retain some engraftment capacity and, for these
reasons, we feel it is appropriate to continue to refer to the en-
tire population as LT-HSC.
Our results indicate that LT-HSC are maintained in G0
phase of the cell cycle through the concerted action of high
levels of Ckis, and predominant expression of p130–E2F4
complexes, which are thought to transcriptionally repress
most of the E2F target genes involved in S phase progression
(7). Together, these factors preclude accumulation of high
levels of cyclins (mostly mitotic cyclins) and limit LT-HSC
proliferation rates. Although every member of the Ink4 and
Cip/Kip families of Ckis is highly expressed in LT-HSC,
they are not functionally equivalent in preserving HSC qui-
escence. Analyses of p21 and p18 knockout mice have dem-
onstrated their critical functions in maintaining normal num-
bers of resting LT-HSC capable of long-term engraftment
and multilineage reconstitution (8, 10). In contrast, p27-null
mice have a normal HSC compartment but show increased
numbers of progenitor cells (9), whereas p16-null mice spe-
cifically develop thymic hyperplasia (31) and p19- or p57-
deficient mice do not show overt hematopoietic abnormali-
ties (32, 33). These results suggest that these Ckis are ei-
ther dispensable for HSC function or are highly specialized
in controlling proliferation in subsets of differentiating he-
matopoietic cells. However, further investigation may un-
cover additional functions in controlling HSC proliferation.
Hence, the recent study of bmi-1 knockout mice demon-
strated a novel and critical function for p16 in regulating
adult HSC self-renewing proliferation (11), which was not
previously appreciated in p16-null mice (31). Mice deficient
for single Rb proteins or for E2F4 also show defects in vari-
ous hematopoietic lineages (34) but have not yet been ana-
lyzed specifically for changes in the stem cell compartment.
Future investigations will therefore be required to assay their
importance in controlling HSC quiescence.
Although analyses of genetically modified mice are usu-
ally performed to demonstrate the functional involvement of
specific cell cycle components in regulating stem and pro-
genitor cell proliferation, these in vivo approaches have also
their limitations. A good example comes from analyses of the
Figure 7. Molecular networks linking proliferation and cell fate 
decision in HSC and progenitor cells. Summary of the proliferation index, 
phase of the cell cycle, and status of the cell cycle machinery associated 
with differentiation, self-renewal, or long-term engraftment capacity in 
HSC and progenitor cells. Several regulators of the cell cycle found to be 
specifically associated with maintenance of quiescence, differentiation, 
self-renewal, expansion, and mobilization are identified (underlined and 
bold). Such genes represent potential targets to encourage self-renewal, 
prevent differentiation, and reestablish quiescence during ex vivo expansion 
of HSC for clinical transplantation. They also represent potential targets for 
deregulation during leukemic transformation.
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D cyclin–Cdk4-6 complexes, whose critical function during
hematopoietic development has only recently been appreci-
ated through the generation of D1/D2/D3 triple knockout
(12) and Cdk4/6 double knockout (13) mice. Both mice
have complete hematopoietic failure starting at the HSC
level and die during late embryonic development due, in
part, to severe anemia. However, none of the single or dou-
ble D cyclins knockout mice previously analyzed display ma-
jor hematopoietic defects or impaired HSC function. This
result emphasizes the functional redundancy existing in vivo
between the three D cyclins that limits the understanding of
their specific function during hematopoiesis. Our analysis
sheds new light on the involvement of each particular D cy-
clin in controlling stem and progenitor fates (Fig. 7). Hence,
HSC differentiation specifically associates with cyclin D1 in-
duction, whereas self-renewing HSC do not show induction
of cyclin D1. Furthermore, myeloid differentiation only cor-
relates with cyclin D2 induction, whereas lymphoid differ-
entiation specifically associates with cyclin D3 induction.
Together, these findings suggest that specific cellular out-
comes may be effected by the induction of a particular D cy-
clins. In addition, differentiating HSC show specific induc-
tion of cyclins G2 and B1, whereas self-renewing HSC
display specific induction of cyclin G1 and B2 and no
change in cyclin G2 expression (Fig. 7). Hence, cyclin D1,
cyclin G2, and, to a lower extent, cyclin B1 may be privi-
leged mediators of HSC differentiation-associated prolifera-
tion, whereas cyclin G1 and cyclin B2 could be privileged
mediators of HSC self-renewal–associated proliferation. HSC
fate determination is controlled by many intrinsic and ex-
trinsic signals, which act through regulation of different sig-
naling pathways. Because all these pathways must eventually
converge on cell cycle regulation, it is conceivable that one
might drive HSC fate determination by directly manipulat-
ing the expression levels of specific components and regula-
tors of the cell cycle machinery, as suggested by the recent
demonstration that ex vivo targeting of the Cki p21 permits
a relative expansion of human HSC (35). Our results pro-
vide a molecular basis for the rational design of strategies to
test whether inactivation or activation of specific sets of cy-
clins may prevent differentiation and favor self-renewal pro-
liferation during ex vivo expansion of HSC.
In conclusion, understanding the particular transcrip-
tional programs used by HSC as they exit quiescence and
transit through the cell cycle are likely to reveal how HSC
fate decisions are regulated at the molecular level and to pro-
vide ways to allow their manipulation for clinical applica-
tions. Moreover, because leukemia (and other cancer) stem
cells also undergo similar self-renewal versus differentiation
cell fate decisions (36), identifying the key entities involved
in these decisions could reveal new molecular targets for hu-
man therapies.
MATERIALS AND METHODS
Mice. 4–6-wk-old C57BL/6-Thy1.1 mice were used as donors for all stem,
progenitor, and mature cell populations. BrdU (Sigma-Aldrich) was adminis-
trated by intraperitoneal injection (1 mg/mouse) as a single dose or as repeated
doses every 6 h. Cytokine mobilization of HSC by combined administration
of Cy/G was performed as previously described (4). For transplantation exper-
iments, cells were purified from C57BL/6-Thy1.1-Ly5.1 mice and trans-
planted via retroorbital injection into lethally irradiated (950 rad) C57/B6-
Ly5.2 congenic recipient mice. Peripheral blood was obtained from the tail
vein of each mouse and analyzed by flow cytometry. Donor-derived cells were
distinguished from host cells by the expression of different Ly5 antigens (Ly5.1
vs. Ly5.2). All mice were maintained in Stanford University’s Research Ani-
mal Facility in accordance with institutional guidelines.
Cell sorting. Cell staining and enrichment procedures for sorting of mul-
tipotent BM cells (LT-HSC, ST-HSCF, and MPPF), KTLS HSC, myeloid
progenitors (CMP, GMP, and MEP), and lymphoid progenitors (CLP)
were performed as previously described (19–22). Cells were finally resus-
pended in HBSS with 2% heat-inactivated FCS and 1 g/ml PI and sorted
on a FACSVantage (Becton Dickinson). Dead cells were gated out by high
PI staining and forward light scatter.
BrdU staining. Double FACS–sorted stem, progenitor, and mature cell
populations were fixed in 70% ethanol overnight at 20C, denatured in
2N HCL/0.5% Triton X-100 for 20 min at room temperature, neutralized
with 0.1 M sodium borate for 5 min, and stained with anti-BrdU antibody
(BD Biosciences) for 30 min at room temperature in PBS/0.5% BSA/0.5%
Tween 20. Cells were finally resuspended in 500 l PBS containing 10 g
RNase A and 5 g PI, incubated for 30 min, and immediately analyzed on
a FACScan (Becton Dickinson).
H/PY staining. Double FACS–sorted stem, progenitor, and mature cell
populations were incubated for 45 min at 37C with 20 g/ml HOECHST
33342 (Invitrogen) in HBSS medium containing 10% FCS, 20 mM Hepes, 1
g/liter glucose, and 50 g/ml Verapamil as described previously (5). Pyronin
Y (Sigma-Aldrich) was then added at 1 g/ml, and the cells were incubated
for another 15 min at 37C, washed, and immediately analyzed or sorted by
flow cytometry on a UV laser–equipped Flasher II MoFlo (DakoCytomation).
qRT-PCR. Total RNA was isolated using Trizol reagent (Invitrogen) from
equivalent numbers of double FACS–sorted stem, progenitor, and mature cell
populations (1,000–8,000 cells), digested with DNase I to remove DNA con-
tamination, and used for RT according to the manufacturer’s instructions
(SuperScript II kit; Invitrogen). qRT-PCR primers were designed using
Primer Express software (Applied Biosystems; Table S1, available at http://
www.jem.org/cgi/content/full/jem.20050967/DC1). All reactions were
performed in an ABI-7000 sequence detection system using SYBR green
PCR Core reagents according to the manufacturer’s instructions (Applied
Biosystems). PCR amplification was performed in a 10-l final volume con-
taining 1 SYBR Green PCR buffer, 2 mM magnesium chloride, 0.5 mM
dNTP mix with dUTP, 8 ng of each primer, 0.1 U AmpErase UNG, 0.25 U
AmpliTaq Gold, and 1 l of cDNA templates (cDNA equivalent of 50 cells
per reaction) using 50C for 2 min and 95C for 10 min, followed by 45 cy-
cles at 95C for 15 s and 60C for 1 min. For each sample, expression of the

-actin gene was used to normalize the amount of the investigated transcript.
Statistical analyses were performed using Student’s t test for two samples.
Online supplemental material. Fig. S1 depicts the proliferation capacity
of LT-HSC cell cycle subpopulations. Fig. S2 shows the cell cycle distribu-
tion in progenitor and mature cell populations. Fig. S3 depicts the differen-
tial expression of components and regulators of the cell cycle machinery in
stem, progenitor, and mature cell populations. Fig. S4 shows that mobilized
D4 mpb HSC originate from recently divided HSC. Table S1 provides se-
quences of qRT-PCR primers. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20050967/DC1.
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